Related Experiment Video

Updated: Apr 7, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.5K

Sorafenib: 10 years after the first pivotal trial

Gennaro Gadaleta-Caldarola1, Stefania Infusino2, Rosa Divella3

  • 1Medical Oncology Unit, 'Mons. R Dimiccoli' Hospital, Viale Ippocrate, 15, 76121 Barletta, Asl BAT, Italy.

Future Oncology (London, England)
|July 11, 2015
PubMed

Insights

Sorafenib, an oral multikinase inhibitor, shows anticancer efficacy in liver, kidney, and thyroid cancers. This review covers its safety, use in new drug development, and potential in other advanced solid tumors.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Sorafenib is an oral multikinase inhibitor.
  • It is approved for hepatocellular carcinoma, advanced renal cell carcinoma, and differentiated thyroid carcinoma.

Purpose of the Study:

  • To review studies on sorafenib's efficacy and safety.
  • To discuss future perspectives for sorafenib use.

Main Methods:

  • Literature review of studies investigating sorafenib.
  • Analysis of sorafenib's role in drug development and combination therapies.

Main Results:

  • Sorafenib demonstrates anticancer activity across various solid tumors.
  • Established efficacy and safety profiles in approved indications.
  • Potential for combination therapies and use in refractory tumors.

Conclusions:

  • Sorafenib is a valuable treatment option for specific cancers.
  • Further research is warranted for its expanded use and combination strategies.
Keywords:
GISTHCCNSCLCbreast cancermRCCmelanomaquality of lifesarcomasorafenibthyroid cancer

More Related Videos

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K
Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

639

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K